Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total value of $4,560,000.00. Following the completion of the transaction, the chief financial officer now owns 12,278,992 shares in the company, valued at $139,980,508.80. The trade was a 3.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Verona Pharma Trading Up 0.5%
Shares of Verona Pharma stock traded up $0.50 during midday trading on Monday, reaching $92.70. The company had a trading volume of 974,523 shares, compared to its average volume of 1,322,629. The stock has a fifty day moving average price of $71.85 and a 200 day moving average price of $60.92. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The firm has a market cap of $7.52 billion, a PE ratio of -48.28 and a beta of 0.21. Verona Pharma plc has a fifty-two week low of $14.14 and a fifty-two week high of $94.77.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million. On average, equities analysts anticipate that Verona Pharma plc will post -1.95 earnings per share for the current year.
Hedge Funds Weigh In On Verona Pharma
Several institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. lifted its stake in Verona Pharma by 2.2% in the first quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company's stock valued at $219,539,000 after buying an additional 73,900 shares during the period. Wellington Management Group LLP lifted its stake in Verona Pharma by 61.0% in the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock valued at $140,492,000 after buying an additional 1,146,609 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Verona Pharma by 1.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company's stock valued at $118,491,000 after buying an additional 32,748 shares during the period. RTW Investments LP acquired a new position in Verona Pharma in the fourth quarter valued at approximately $84,568,000. Finally, Janus Henderson Group PLC lifted its stake in Verona Pharma by 59.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock valued at $77,466,000 after buying an additional 624,370 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
VRNA has been the topic of a number of recent analyst reports. TD Cowen initiated coverage on Verona Pharma in a research report on Monday, April 28th. They issued a "buy" rating and a $100.00 target price on the stock. Cantor Fitzgerald lifted their target price on Verona Pharma from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Jefferies Financial Group lifted their target price on Verona Pharma from $95.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Wells Fargo & Company lifted their target price on Verona Pharma from $93.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. Finally, Roth Capital set a $83.00 target price on Verona Pharma in a research report on Friday, February 28th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Verona Pharma currently has an average rating of "Buy" and an average target price of $87.44.
Check Out Our Latest Research Report on VRNA
Verona Pharma Company Profile
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
See Also
Before you consider Verona Pharma PLC American Depositary Share, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma PLC American Depositary Share wasn't on the list.
While Verona Pharma PLC American Depositary Share currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
